ReviewInfection2015
Novel antibiotics: are we still in the pre-post-antibiotic era?
Review in Infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Machine Learning-Identified Potent Antimicrobial Peptides Against Multidrug-Resistant Bacteria and Skin Infections.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Peptides: The Production of Novel Peptide-Based Therapeutics in Plant Systems.Life (Basel, Switzerland) · 2023Review
- Activation of multiple stress responses inFrontiers in microbiology · 2023Article
- The design and evaluation of the antimicrobial activity of a novel conjugated penta-ultrashort antimicrobial peptide in combination with conventional antibiotics against sensitive and resistant strains ofResearch in pharmaceutical sciences · 2022Article
- Antibacterial, Antibiofilm, and Antioxidant Activity of 15 Different Plant-Based Natural Compounds in Comparison with Ciprofloxacin and Gentamicin.Antibiotics (Basel, Switzerland) · 2022Article
- Super-Cationic Peptide Dendrimers-Synthesis and Evaluation as Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2021Article
- Fecal carriage of ESBL-producingAIMS microbiology · 2020Article
- Antimicrobial Peptides as Anti-Infective Agents in Pre-Post-Antibiotic Era?International journal of molecular sciences · 2019Review
- The role of mass spectrometry in antibiotic stewardship.Clinical mass spectrometry (Del Mar, Calif.) · 2019Review
- Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs.Critical reviews in microbiology · 2019Review
- Physical and chemical stability of ceftaroline in an elastomeric infusion device.European journal of hospital pharmacy : science and practice · 2018Article
- Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function.Journal of clinical pharmacology · 2018Article
- Design, Synthesis and Evaluation of Branched RRWQWR-Based Peptides as Antibacterial Agents Against Clinically Relevant Gram-Positive and Gram-Negative Pathogens.Frontiers in microbiology · 2018Article
- In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus.Molecules (Basel, Switzerland) · 2017Article
- Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.The Journal of antibiotics · 2017Review
- Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes.Current opinion in microbiology · 2016Review
- Recent Advances in Antimicrobial Polymers: A Mini-Review.International journal of molecular sciences · 2016Review
- Blue sky and some shadows: new antibiotics and new superbugs : The ECCMID 2016 in Amsterdam.Infection · 2016Article
- In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate.Scientific reports · 2016Article
- Persistent Bacteremia fromCase reports in infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTherapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed.
methodsThis paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials.
conclusionEach of these new trials increases the possibility of new antibiotics receiving approval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.